Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics INC (KPTI)
:KPTI
Ruxolitinib, Pacritinib, Momelotinib, Selinexor 60 Mg, Selinexor 40 Mg
Myelofibrosis, Moderate Thrombocytopenia
Phase II
Recruiting
A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Jul 24, 2023
―
Selinexor
Endometrial Cancer
Phase III
Recruiting
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Nov 03, 2022
―
Pembrolizumab, Selinexor, Trifluridine, Tipiracil
Metastatic Colorectal Cancer
Phase II
Terminated
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
Apr 17, 2021
―
Lenalidomide, Daratumumab, Selinexor, Dexamethasone Oral
Multiple Myeloma, Plasma Cell Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell, Myeloma-Multiple, Myelomatosis
Phase II
Active Not Recruiting
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
Mar 01, 2021
―
Pembrolizumab, Selinexor
Locally Advanced Unresectable Or Metastatic Melanoma
Phase II
Terminated
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Feb 22, 2021
―
Lenalidomide, Oxaliplatin, Gemcitabine, Venetoclax, Rituximab, Selinexor, Bendamustine, Ibrutinib, Polatuzumab Vedotin, Tafasitamab
Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
Phase I/II
Suspended
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Oct 26, 2020
―
Ruxolitinib, Selinexor
Myelofibrosis
Phase III
Recruiting
Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis
Sep 14, 2020
―
Selinexor, Physician's Choice Treatment
Myelofibrosis
Phase II
Active Not Recruiting
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis
Sep 09, 2020
―
Lenalidomide, Selinexor, Methylprednisolone
Refractory Multiple Myeloma
Phase I
Recruiting
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
Aug 12, 2020
―
Selinexor (Combination Therapy), Rituximab (Combination Therapy), Gemcitabine (Combination Therapy), Dexamethasone (Combination Therapy), Cisplatin (Combination Therapy), Selinexor (Continuous Therapy)
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase II/III
Recruiting
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
Jun 10, 2020
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Karyopharm Therapeutics INC (KPTI) have in its pipeline
KPTI is currently developing the following drugs: Ruxolitinib, Pacritinib, Momelotinib, Selinexor 60 Mg, Selinexor 40 Mg, Selinexor, Pembrolizumab, Selinexor, Trifluridine, Tipiracil. These drug candidates are in various stages of clinical development as the company works toward FDA approval.